Company profile
VistaGen Therapeutics, Inc.
NASDAQ: VTGN · Healthcare · Biotechnology
#856 of 1,422 Healthcare companies by revenuetop-quartile growth
EA Score
46DFH 28DQ 65GM 56SS 53
v0.1 · 65/100 weight · provisional
↑ revenue growth (YoY), disclosure history · ↓ operating margin, net margin
Methodology →Revenue TTM
$1.3M
Rev growth YoY (TTM)
+161.3%
Net income (FY)
-$69.7M
Employees
41
as of 2026-08-23
Market cap
$10.8M
as of 2026-08-23
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$1.3M$1.3M2026
Net income-$69.7M-$69.7M2026
Operating income-$72.1M-$72.1M2026
Total assets$48.6M$48.6M2026
Liabilities$13.0M$13.0M2026
Equity$35.5M$35.5M2026
Revenue trend
FY2022 – FY2026 · USD
FY22
FY23
FY23
FY23
FY23
FY24
FY25
FY26
Revenue by segment
Filed disclosures · FY2022
By product
License100%
By geography
Not disclosed.
The read
What is VistaGen Therapeutics, Inc.’s revenue?
VistaGen Therapeutics, Inc. booked $1.3M in FY2026 revenue, growing 161% year over year — faster than most Healthcare companies we track, at a -5491.3% net margin.
Peers · Healthcare
Inhibrx Biosciences Inc.28DBhang Inc.——Certive Solutions Inc.——Baudax Bio, Inc.——SeaStar Medical Holding Corporation30DNRx Pharmaceuticals, Inc.24DNeighbors
San Mateo →Key facts
CEOShawn K. Singh
SectorHealthcare
IndustryBiotechnology
HeadquartersSouth San Francisco, CA
ExchangeNASDAQ: VTGN
Employees41
IPO date2011-06-21
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.